288 Appendices 67. Dickhoff C, Senan S, Schneiders FL, et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 nonsmall cell lung cancer: The INCREASE trial. BMC Cancer. 2020;20(1):1-10. doi:10.1186/s12885020-07263-9 68. Underwood JCE, Crocker J. Pathology of the Nucleus. Springer; 1990. 69. Uhler C, Shivashankar G V. Nuclear Mechanopathology and Cancer Diagnosis. Trends in Cancer. 2018;4(4):320-331. doi:10.1016/j.trecan.2018.02.009 70. Fajardo LP BM. Radiation injury in surgical pathology. Part 1. Am J Surg Pathol. 1978;(2):159199. 71. Poeze M, Von Meyenfeldt MF, Peterse JL, et al. Increased proliferative activity and p53 expression in normal glandular breast tissue after radiation therapy. J Pathol. 1998;185(1):32-37. doi:10.1002/(SICI)1096-9896(199805)185:1<32::AID-PATH43>3.0.CO;2-Q 72. Buhmeida A, Ålgars A, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S. Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma. Anticancer Res. 2006;26(1 B):455-462. 73. Kadota K, Miyai Y, Katsuki N, et al. Nuclear grade based on transbronchial cytology is an independent prognostic factor in patients with advanced, unresectable non-small cell lung cancer. Cancer Cytopathol. 2016;124(9):630-640. doi:10.1002/cncy.21736 74. Siva S, Lobachevsky P, MacManus MP, et al. Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues. Clin Cancer Res. 2016;22(19):4817-4826. doi:10.1158/1078-0432.CCR-16-0138 75. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumor Biol. 2010;31(4):363-372. doi:10.1007/s13277-010-0042-8 76. Sellers AH. The clinical classification of malignant tumours: the TNM system. Can Med Assoc J. 1971;105(8):836 passim. http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=1931208&tool=pmcentrez&rendertype=abstract 77. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2(8):706-714. doi:10.1097/ JTO.0b013e31812f3c1a 78. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2007;2(7):593-602. doi:10.1097/ JTO.0b013e31807a2f81 79. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(7):990-1003. doi:10.1097/ JTO.0000000000000559 80. Casparie M, Tiebosch ATMG, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19-24. doi:10.1155/2007/971816 81. Ueda K, Tanaka T, Hayashi M, et al. Compensation of pulmonary function after upper lobectomy versus lower lobectomy. J Thorac Cardiovasc Surg. 2011;142(4):762-767. doi:10.1016/j.jtcvs.2011.04.037 82. CBS. CBS data 2016. http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=03743&D 1=0&D2=0,2&D3=0,8-206&D4=0,4,9,14,18-20&HDR=T,G1,G3&STB=G2&VW=T. 83. Oncoline. No Title. https://www.oncoline.nl/niet-kleincellig-longcarcinoom. 84. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(June):iv1-iv21. doi:10.1093/annonc/mdx222
RkJQdWJsaXNoZXIy MTk4NDMw